The disclosure features, inter alia, combination therapies comprising durvalumab and one or more immunogenic XBP1-, CD138-, and CS1-derived peptides. The therapies herein can be used, e.g., for inducing an immune response in a subject having a solid tumor, and treating a solid tumor, e.g., breast cancer, e.g., triple negative breast cancer.
